Spray-on skin technology saving lives of many in Australia and around the world

The Bali bombing in 2002 caused the shocking deaths of 202 people, including 88 Australians. A further 209 were injured, many with disfiguring burns. But thanks to plastic surgeon Professor Fiona Wood, from the Royal Perth Hospital, a spray-on skin she invented saved many lives. RECELL continues to do so today around the world, thanks […]

BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks

Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]

BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award

Melbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]

New industry Advisory Group Chairs appointed by AusBiotech

Link to Full Article AusBiotech welcomes its new industry Advisory Group Chairs: Dr Megan Robertson, St Vincent’s Hospital Melbourne, Chair of the AusBiotech Clinical Trials Adivsory Group; and Dr Amanda Gillon, Bioscience Managers, Chair of the AusBiotech Investor Advisory Group. AusBiotech’s national advisory groups and state branch committees are important mechanisms to highlight and address […]

BioScience Managers invests in CSIRO-derived microencapsulation technology

Melbourne, Australia and London, UK 8 August 2019 – BioScience Managers (BSM), one of Australia’s leading international healthcare investment firms, today announces an investment in Sydney-based nutrition technology company, Pharmamark Nutrition Pty. Ltd. BSM has invested A$5.5 million in Pharmamark Nutrition. The funds will go toward the development of CSIRO’s microencapsulation technology for Pharmamark’s IntEncap™ product […]

Healthcare Investing: Wealth Managers Chart Way Forward

Link to full Article Will Brooks and Jeremy Curnock Cook, 17 April 2019 The healthcare sector has seen huge investment growth and more specialised products starting to emerge. Two specialists navigate what is on offer. Global spending on healthcare is projected to reach $10 trillion by 2022. Venture capital flowing into UK medtech companies has […]

UK biotech industry surges by 65%, giving hope· as Brexit looms

London and Oxbridge ‘Golden Triangle’ retains top position, hosting 1 in 3 biotechs The number of UK  biotechs  has  increased by 65%  in the  last  three years,  according to analysis by London -based investment management firm Downing LLP.  The growth has  been  fueled  by record  levels of investment as the UK biotech industry attracted £2.2 […]

Venture capital biotech funding increases 35% year on year

28 MAR 2019 Link to article Venture capital channels over £2m a day into biotech, accounting for two thirds of all biotech funding Venture capital funding for UK biotechnology has increased by 35 per cent year on year to £182 million in the first quarter of 2019. This compares with £135 million in Q1 2018. […]

BioScience Managers appoints Dr. Kate Rowley as UK-based Investment Director

London, UK and Melbourne, Australia, 30 October 2018 – BioScience Managers Limited (BioScience Managers), the international healthcare investment firm today announces the appointment of Dr. Kate Rowley as Investment Director, based in London. Reflecting BioScience Managers’ international focus Dr. Rowley’s role will be to review and evaluate healthcare investment opportunities and manage investment deals from […]

Downing FOUR VCT invests £1.14 million in ADC Biotechnology Ltd

Investment from Downing FOUR VCT (Healthcare and General share classes) advised by BioScience Managers Limited Funds used to progress development of Antibody Drug Conjugate (ADCs) technology Downing FOUR VCT is targeting dividends of at least 4% p.a. (of net assets) from the fourth year onwards * London, UK, 24 April 2018 – London-based investment management […]